FluoGuide (FLUO) Stock Overview
A clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
FLUO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
FluoGuide A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 31.70 |
| 52 Week High | SEK 47.60 |
| 52 Week Low | SEK 29.10 |
| Beta | 0 |
| 1 Month Change | -4.23% |
| 3 Month Change | -15.69% |
| 1 Year Change | -22.87% |
| 3 Year Change | -66.91% |
| 5 Year Change | -74.94% |
| Change since IPO | 472.20% |
Recent News & Updates
Recent updates
Regulatory Alignment And Phase II Success Will Support A Wider Surgical Imaging Opportunity
Catalysts About FluoGuide FluoGuide develops imaging agents that light up cancer during surgery to help surgeons remove tumors more precisely. What are the underlying business or industry changes driving this perspective?Health Check: How Prudently Does FluoGuide (STO:FLUO) Use Debt?
Jul 26
Here's Why We're Watching FluoGuide's (STO:FLUO) Cash Burn Situation
Jan 22Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth
Jan 27FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans
Oct 07We're Hopeful That FluoGuide (STO:FLUO) Will Use Its Cash Wisely
May 21FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans
Jan 31Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth
Feb 25Shareholder Returns
| FLUO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -7.0% | 3.0% | 0.3% |
| 1Y | -22.9% | 13.9% | 7.0% |
Return vs Industry: FLUO underperformed the Swedish Biotechs industry which returned 13.9% over the past year.
Return vs Market: FLUO underperformed the Swedish Market which returned 7% over the past year.
Price Volatility
| FLUO volatility | |
|---|---|
| FLUO Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 12.7% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: FLUO has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: FLUO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 7 | Morten Albrechtsen | fluoguide.com |
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer.
FluoGuide A/S Fundamentals Summary
| FLUO fundamental statistics | |
|---|---|
| Market cap | SEK 536.26m |
| Earnings (TTM) | -SEK 56.34m |
| Revenue (TTM) | SEK 314.12k |
Is FLUO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FLUO income statement (TTM) | |
|---|---|
| Revenue | DKK 220.00k |
| Cost of Revenue | DKK 0 |
| Gross Profit | DKK 220.00k |
| Other Expenses | DKK 39.68m |
| Earnings | -DKK 39.46m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 27, 2026
| Earnings per share (EPS) | -2.41 |
| Gross Margin | 100.00% |
| Net Profit Margin | -17,935.91% |
| Debt/Equity Ratio | 50.6% |
How did FLUO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/11 19:22 |
| End of Day Share Price | 2026/03/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
FluoGuide A/S is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christian Binder | Redeye |